Allergan plc announced today it has received marketing authorization from the U.S. FDA for its TrueTear™ Intranasal Tear Neurostimulator — reportedly the first and only FDA-cleared device developed to temporarily increase tear production during neurostimulation in adult patients.
According to Allergan, TrueTear is a handheld stimulator with daily disposable tips that is inserted into the nasal cavity to induce the production of tears. There have reportedly been two clinical studies showing positive safety and effectiveness of the device in the increase of tear production completed with 145 aqueous deficient dry eye adult patients.
Click here to read the full press release.
Additionally, Allergan was recently named a 2017 ENERGY STAR Partner of the Year – Sustained Excellence Award winner. The company was reportedly recognized for its continued leadership in protecting the environment through superior energy efficiency achievements.
Click here to read the full press release.
Like what you read? Follow OphthalmologyWeb to keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox.